Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pyrimethamine + sulfadiazine + prednisolone
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy used primarily for treating ocular toxoplasmosis. Pyrimethamine and sulfadiazine work synergistically to inhibit folate biosynthesis in Toxoplasma gondii, while prednisolone reduces inflammation and tissue damage. This regimen is considered the classic first-line treatment for ocular toxoplasmosis.
- Other names
- classic treatment of ocular toxoplasmosis
02
Targets
DHPS (Dihydropteroate synthase)DHFR (Dihydrofolate reductase)GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on pyrimethamine + sulfadiazine + prednisolone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pyrimethamine + sulfadiazine + prednisolone.